Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) have been given a consensus recommendation of “Hold” by the eleven ratings firms that are currently covering the company, Marketbeat reports. Three research analysts have rated the stock with a sell recommendation, two have given a hold recommendation and six have issued a buy recommendation on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $8.08.

Several research analysts have recently weighed in on CLDX shares. HC Wainwright set a $10.00 price target on shares of Celldex Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, August 9th. Zacks Investment Research upgraded shares of Celldex Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price target on the stock in a research note on Tuesday, July 11th. Aegis restated a “buy” rating on shares of Celldex Therapeutics in a research note on Thursday, June 29th. Cowen and Company restated a “buy” rating on shares of Celldex Therapeutics in a research note on Tuesday, June 6th. Finally, Jefferies Group LLC restated a “hold” rating and set a $3.50 target price (down previously from $4.00) on shares of Celldex Therapeutics in a research note on Thursday, May 11th.

Celldex Therapeutics (NASDAQ:CLDX) traded down 1.27% on Friday, hitting $2.33. 726,077 shares of the stock traded hands. The stock’s market cap is $299.03 million. Celldex Therapeutics has a 52-week low of $2.20 and a 52-week high of $5.02. The company’s 50 day moving average price is $2.44 and its 200-day moving average price is $2.97.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.28) by $0.05. The business had revenue of $3.83 million for the quarter, compared to analysts’ expectations of $1.21 million. Celldex Therapeutics had a negative net margin of 1,318.94% and a negative return on equity of 51.87%. The company’s revenue was up 175.5% compared to the same quarter last year. During the same quarter last year, the company posted ($0.32) EPS. On average, analysts forecast that Celldex Therapeutics will post ($1.04) earnings per share for the current fiscal year.

Several hedge funds have recently bought and sold shares of CLDX. Raymond James Financial Services Advisors Inc. increased its stake in Celldex Therapeutics by 26.2% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 28,885 shares of the biopharmaceutical company’s stock worth $104,000 after buying an additional 6,000 shares during the period. BB&T Securities LLC acquired a new stake in Celldex Therapeutics during the second quarter worth $117,000. Voya Investment Management LLC increased its stake in Celldex Therapeutics by 17.4% in the second quarter. Voya Investment Management LLC now owns 50,535 shares of the biopharmaceutical company’s stock worth $125,000 after buying an additional 7,499 shares during the period. Overbrook Management Corp acquired a new stake in Celldex Therapeutics during the second quarter worth $139,000. Finally, Pacad Investment Ltd. acquired a new stake in Celldex Therapeutics during the second quarter worth $150,000. Hedge funds and other institutional investors own 63.88% of the company’s stock.

WARNING: “Celldex Therapeutics, Inc. (CLDX) Receives Average Recommendation of “Hold” from Brokerages” was originally reported by Daily Political and is the property of of Daily Political. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://www.dailypolitical.com/2017/08/19/celldex-therapeutics-inc-cldx-receives-average-recommendation-of-hold-from-brokerages.html.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Analyst Recommendations for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.